Future prospects of neoadjuvant chemotherapy in treatment of primary breast cancer

Seminars in Surgical Oncology

Volumn 12, Issue 1, 1996, Pages 59-66

  Wang, Hwei Chung ^a,b   Lo, S U Shun ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

locally advanced breast cancer; neoadjuvant chemotherapy; resectable breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; PREDNISONE; THIOTEPA; VINBLASTINE; VINCRISTINE; VINDESINE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FORECASTING; HUMANS;

EID: 0030041254     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199601/02)12:1<59::AID-SSU9>3.0.CO;2-5     Document Type: Review

References (82)

1. De Vita VT: On the value of response criteria in therapeutic research. In Jacquillat CI, Weil M, Khayat D (eds): "Neoadjuvant Chemotherapy." Paris: John Libby Eurotex, 1988, 3-14.
2. Skipper HE, Schabel FM Jr, Wilcox WS: Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35:1-111, 1964.
3. Goldie JH, Coldman AJ: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979.
4. Goldie JH, Coldman AJ, Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439-449, 1982.
5. Goldie JH, Coldman AJ: Current status of mutational theories for the origin of drug resistance in neoplasms. In Salmon SE (ed): "Adjuvant Therapy of Cancer " Vol. VI. Philadelphia: WB Saunders, 1990, 21-25.
6. Goldie JH, Coldman AJ: Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep 67:923-931.
7. Goldie JH: Mathematical models to predict behavior of tumors? Eur J Cancer Clin Oncol 24:587-589, 1988.
8. De Vita VT Jr: The James Ewing lecture. The relationship between tumor mass and resistance to chemotherapy: Implications for surgical adjuvant treatment of cancer. Cancer 51:1209-1220, 1983.
9. Schabel FM Jr: Concepts for treatment of micrometastases developed in murine systems. AJR 126:500-511, 1976.
10. Schabel FM Jr: Surgical adjuvant chemotherapy of metastatic murine tumors. Cancer 40:558-568, 1977.
11. Goldie JH: Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol 14:1-7, 1987.
12. Shapiro DM, Fugmann RA: A role for chemotherapy as an adjunct to surgery. Cancer Res 17:1098-1101, 1957.
13. Martin DS, Fugmann RA: Clinical implications of the interrelationship of tumor size and chemotherapeutic response. Ann Surg 151:97-100, 1960.
14. Schabel FM Jr: Concepts for systemic treatment of micrometastases. Cancer 35:15-24, 1975.
15. Salmon SE: Kinetics of minimal residual disease. Recent Results Cancer Res 67:1-15, 1979.
16. Goldie JH, Walker M, Kelly L, et al: Free tumor cell growth in the peritoneal cavity (ascites tumor) of mice bearing subcutaneous tumors. Cancer Res 16:553-558, 1956.
17. Goodman GJ: Effects of one tumor upon the growth of another. Proc Am Assoc Cancer Res 2:207, 1957.
18. Ketcham AS, Kinsey DL, Wexler H, et al: The development of spontaneous metastases after the removal of a primary tumor. II. Standardization protocol of five animal tumors. Cancer 14:875-882, 1961.
19. Ketcham AS, Wexler H, Mantel N: The effect of removal of a "primary" tumor on the development of spontaneous metastases. I. Development of a standardized experimental technique. Cancer Res 19:940-944, 1959.
20. DeWys WD: Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res 32:374-379, 1972.
21. Fisher B, Gunduz N, Saffer E: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastaes. Cancer Res 43:1488-1492, 1983.
22. Fisher B, Saffer EA, Deutsch M: Influence of irradiation of a primary tumor on the labeling index and estrogen receptor index in a distant tumor focus. Int J Radiat Oncol Biol Phys 12:879-885, 1986.
23. Surgical Adjuvant Chemotherapy Breast Group: Breast adjuvant chemotherapy: Effectiveness of THIOTEPA as adjuvant to radical mastectomy for breast cancer. Ann Surg 154:629-647, 1961.
24. Fisher B, Redmond C, Fisher ER, et al: A summary of findings from NSABP trials of adjuvant therapy. In Jones SE, Salmon SE (eds): "Adjuvant Therapy of Cancer." Vol. IV. Orlando, FL: Grune & Stratton, 1984, 185-194.
25. Bonadonna G, Valagussa P, Rossi A, et al: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5:95-115, 1985.
26. Yabro JW: Future potential of adjuvant and neoadjuvant therapy. Semin Oncol 18:613-619, 1991.
27. Morrow M, Hoffman PC, Weichselbaumb RR: Locally advanced breast cancer. In Harris JR, Hellman S, Henderson IJ, Kinne DW (eds): "Breast Disease," Philadelphia: JB Lippincott, 1991, 767-774.
28. Haagensen CD: Clinical classification of the stage of advancement of breast carcinoma. In Haagensen CD (ed): "Diseases of Breast." Philadelphia: WB Saunders, 1986, 851-863.
29. Stoker TAM. The place of surgical excision in the management of locally advanced breast cancer. Cancer Treat Rev 1:27-37, 1974.
30. Davila E, Vogel CL: Management of locally advanced breast cancer (stage III): A review. Int Adv Surg Oncol 7:297-327, 1984.
31. Haagensen CD. Inflammatory carcinoma. In Haagensen CD (ed): "Diseases of the Breast." Philadelphia: WB Saunders, 1986, 808-814.
32. Zucali R, Uslenghi C, Kenda R, Bonadonna G: Natural history and survival of inoperable breast cancer treated with radiotherapy followed by radical mastectomy. Cancer 37:1422-1431, 1976.
33. Camp E: Inflammatory carcinoma of the breast, the case for conservatism. Am J Surg 131:583-586, 1976.
34. Chu AM, Wood WC, Doucette JA: Inflammatory breast carcinoma treated by radical radiotherapy. Cancer 45:2730-2737, 1980.
35. Droulias C, Sewell C, McSweeney M, Powell R: Inflammatory carcinoma of the breast: A correlation of clinical radiologic and pathologic findings. Ann Surg 184:217-222, 1976.
36. Bruckman J, Harris J, Levene M, et al: Results of treating stage III carcinoma of the breast by primary radiation therapy. Cancer 30:107-112, 1972.
37. Donegan WL: Staging and primary treatment. In "Cancer of the Breast." 3rd Ed. Philadelphia: WB Saunders, 1988, 390.
38. Fletcher G: Local results of irradiation in the primary management of localized breast cancer. Cancer 29:545-551, 1972.
39. De Lena M, Zucali R, Viganotti G, et al: Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1:53-59, 1978.
40. Rubens RD, Sexton S, Tong D, et al: Combined chemotherapy and radiotherapy for locally advanced breast cancer. Eur J Cancer, 16:351-356, 1980.
41. De Lena M, Varini M, Zucali R, et al: Multimodal treatment for locally advanced breast cancer: Results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 4:229-236, 1981.
42. Hortobagyi GN, Blumenschein GR, Spanos W, et al: Multimodal treatment of locoregionally advanced breast cancer. Cancer 51:763-768, 1983.
43. Zylberberg B, Salat-Baroux J, Ravina JH, et al: Initial chemoimmunotherapy in inflammatory carcinoma of the breast. Cancer 49:1537-1543, 1982.
44. Fastenberg NA, Buzdar AU, Montague ED, et al: Management of inflammatory carcinoma of the breast: A combined modality approach. Am J Clin Oncol 8:134-141, 1985.
45. Feldman LD, Hortobagyi GN, Buzdar AU, et al: Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res, 46:2578-2581, 1986.
46. Bonadonna G: Conceptual and practical advances in the management of breast cancer. J Clin Oncol 7:1380-1397, 1989.
47. Schaake-Koning C, van der Linden EH, Hart G, Engelsman E: Adjuvant chemo-and hormonal therapy in locally advanced breast cancer: A randomized clinical study. Int J Radiat Oncol Biol Phys 11:1759-1763, 1985.
48. Olson JE, Gray R, Sponzo RW, et al: Management of non-resectable locally advanced(stage III) breast cancer: An ECOG trial. Breast Cancer Res Treat 8:109, 1986.
49. Swain M, Sorace RA, Bagley CS, et al: Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 47:3889-3894, 1987.
50. Hortobagyi GN, Buzdar AU, Kau SW, et al: Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 62:2507-2516, 1988.
51. Valagussa P, Zambetti M, Bonadonna G, et al: Prognostic factors in locally advanced noninflammatory breast cancer. Long-term results following primary chemotherapy. Breast Cancer Res Treat 15:137-147, 1990.
52. Lopez MJ, Andriole DP, Kraybill WG, Khojasteh A: Multimodal therapy in locally advanced breast carcinoma. Am J Surg 160:669-675, 1990.
53. Singletary SE, McNeese MD, Hortobagyi GN: Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 69:2849-2852, 1992.
54. Scholl SM, Fourquet A, Asselain B, et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: Preliminary results of a randomized trial: S6. Eur J Cancer 30A: 645-652, 1994.
55. Schwartz GF, Birchansky CA, Komarnicky LT, et al: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73:362-369, 1994.
56. Lippman ME, Sorace A, Bagley CS, et al. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. NCI Monogr 1:153-159, 1986.
57. Piccart MJ, Tomiak KE, Perrault DJ: Systemic treatment for locally advanced breast cancer: What we still need to learn after a decade of multimodality clinical trials. Eur J Cancer 28:667-672, 1992.
58. Tancini G, Bonadonna G, Valagussa P, et al: Adjuvant CMF in breast cancer: Comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1:2-10, 1983.
59. Velez-Garcia E, Moore M, Vogel CL, et al: Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: The Southeastern Cancer Study Group experience. Breast Cancer Res Treat 3 (suppl I):49-60, 1983.
60. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxix therapy on mortality in early breast cancer. N Engl J Med 319:1681-1692, 1988.
61. Valagussa P, Zambetti M, Bignami P, et al: T3b-T4 breast cancer: Factors affecting results in combined modality treatments. Clin Exp Metast 1:191-202, 1983.
62. Harris JR, Morrow M, Bonadonna G: Cancer of the breast. In De Vita VT, Hellman S, Rosenberg SA (eds): "Cancer Principles and Practice of Oncology." Philadelphia: JB Lippincott, 1993, 1264-1332.
63. Bonadonna G: Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52:2127-2137, 1992.
64. Bonadonna G, Valagussa P, Brambilla C, et al: Adjuvant and neoadjuvant treatment of breast cancer with chemotherapy and/or endocrine therapy. Semin Oncol 18:515-524, 1991.
65. Early Breast Cancer Trialists" Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992.
66. Jacquillat C, Weil M, Auclerc G, et al: Neoadjuvant chemotherapy in the conservative management of breast cancer: A study of 252 patients. Recent Results Cancer Res 115:36-42, 1989.
67. Bonadonna G, Veronesi U, Brambilla C, et al: Primary chemotherapy to avoid mastectomy in tumor with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-1545, 1990.
68. Mauriac L, Durand M, Avril A, Dilhuydy J-M: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumor larger than 3 cm. Ann Oncol 2:347-354, 1992.
69. Scholl SM, Asselain B, Palangie T, et al: Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer 27:1668-1671, 1991.
70. Belembaogo E, Feillel V, Chollet P, et al: Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A:896-900, 1992.
71. Morris DM, Edward J, Gelder F: Hormonal receptors in locally advanced breast cancer: Change with response to neoadjuvant chemotherapy? J Surg Oncol 46:156-158, 1991.
72. Hawkins RA, Tesdale AL, Andersen EDC, et al: Does the estrogen receptor concentration of a breast cancer change during systemic therapy? Br J Cancer 61:877-880, 1990.
73. Lo SS, Wang HC, Shyr YM, et al: Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy? J Surg Oncol 57:94-96, 1994.
74. Lo SS, Wang HC, Shyr YM, et al: Can tumor characteristics of primary breast cancer be altered by neoadjuvant chemotherapy? Eur J Surg Oncol 20:367, 1994.
75. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984.
76. Hoogstraten B, George SL, Samal B, et al: Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group Study. Cancer 38:13-20, 1976.
77. Carmo-Perira J, Oliveira Costa F, Herniques E, et al: A comparison of two doses of adriamycin in primary chemotherapy of disseminated breast carcinoma. Br J Cancer 56:471-473, 1987.
78. Shapiro ChL, Henderson IC: High-dose chemotherapy with autologous bone marrow transplantation for breast cancer: promise and perspective. Oncol J Club 2:12-14, 1990.
79. Willemse PHB, de Vries EGE, Sleiyfer DT, et al: Intensive induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with stage IIIB and IV breast cancer. Breast Cancer Res Treat 12:147, 1988.
80. Gianni AM, Bonadonna G: High-dose chemo-radiotherapy for sensitive tumors: Is sequential better than concurrent drug delivery. Eur J Cancer Clin Oncol 25:1627-1630, 1989.
81. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993.
82. Remvikos Y, Beuzeboc P, Zajdela A, et al: Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 81: 1383-1387, 1989.